Fatty acid synthase, the enzyme responsible for fatty acid production in cells, may be a therapeutic target for IPF, a mouse ...

FibroBiologics, Inc. (Nasdaq: FBLG) announced the successful closure of the second $5 million tranche of financing as part of its Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., an ...

FibroBiologics, Inc. ( (FBLG) ) has issued an announcement.

Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of ...

Yorkville agreed to advance to FibroBiologics the first $15 million available under the SEPA in three equal tranches to be evidenced by convertible promissory notes. The first tranche in the amount of ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

Cardiovascular disease continues to lead as the primary cause of death across the globe, taking millions of lives every year.

Cardiovascular disease continues to lead as the primary cause of death across the globe, taking millions of lives every year.

Genescience Pharmaceuticals Co. Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and ...

A research team led by Prof. Li Yu from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of ...